Zweegman S, Stege CAM, Haukas E, Schjesvold FH, Levin MD, Waage A, Leys RBL, Klein SK, Szatkowski D, Axelsson P, Hieu Do T, Knut-Bojanowska D, van der Spek E, Svirskaite A, Klostergaard A, Salomo M, Blimark C, Ypma PF, Mellqvist UH, Poddighe PJ, Stevens-Kroef M, van de Donk NWCJ, Sonneveld P, Hansson M, van der Holt B et al. (2020)
Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial
Haematologica (in press)
DOI 10.3324/haematol.2019.240374, PubMed 32054649

Schjesvold F, Goldschmidt H, Maisnar V, Spicka I, Abildgaard N, Rowlings P, Cain L, Romanus D, Suryanarayan K, Rajkumar V, Odom D, Gnanasakthy A, Dimopoulos M (2019)
Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: the TOURMALINE-MM3 trial
Eur J Haematol (in press)
DOI 10.1111/ejh.13379, PubMed 31880006

Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC, ICARIA-MM study group (2019)
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Lancet, 394 (10214), 2096-2107
DOI 10.1016/S0140-6736(19)32556-5, PubMed 31735560